MGC026

March 9, 2026: MacroGenics, Inc. (NASDAQ: MGNX) reported FY2025 financial results and outlined 2026 pipeline catalysts across its oncology programs.

• MGC026 (B7-H3 ADC): Phase 1 dose escalation enrollment completed in 2025; dose expansion ongoing in selected solid tumors. Initial clinical data expected mid-2026. Company said safety has been acceptable to date with no interstitial lung disease observed and early evidence of anti-tumor activity by RECIST.
• MGC028 (ADAM9 ADC): Ongoing Phase 1 dose escalation in advanced solid tumors. Initial clinical data expected in 2H 2026; acceptable safety to date with no interstitial lung disease observed and early RECIST activity cited.
• MGC030 (TOP1 inhibitor-based ADC): Preclinical, targets an undisclosed solid-tumor antigen. IND submission to FDA planned for 3Q 2026.
• Lorigerlimab (PD-1 × CTLA-4 bispecific DART), Phase 2 LINNET: Monotherapy in platinum-resistant ovarian cancer or clear cell gynecologic cancer. Trial is under an FDA partial clinical hold (no new enrollment); clinical update still planned for mid-2026.

Partner/program updates noted: Gilead collaboration (MGD024 in AML/MDS plus two preclinical programs; up to $1.6B milestones/royalties eligibility); Sanofi TZIELD U.S. expedited review for stage 3 type 1 diabetes (Oct 2025 acceptance); Incyte ZYNYZ approvals in Japan (Dec 2025) and EU for SCAC settings. Cash was $189.9M as of Dec. 31, 2025; runway guided into late 2027.